Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Australia's INOVIQ rises on Sonic Healthcare pact for ovarian cancer test

By Reuters News

** Shares of Australia's INOVIQ IIQ.AX rise as much as 18.5% to A$0.160, marking their biggest intraday pct gain since June 22

** Shares hit their highest level since October 8

** The biotech firm signs validation and licence option agreement with US unit of Sonic Healthcare SHL.AX for its EXO-OC ovarian cancer early detection test

** Says agreement covers transfer, optimisation and validation of EXO-OC at Sonic Healthcare USA's CAP/CLIA-certified molecular diagnostics laboratory in New York

** Adds deal gives Sonic Healthcare USA an option to pursue a future licence to offer EXO-OC as a laboratory-developed test in the United States

** More than 160,000 shares change hands, about 1.9x the 30-day average

** YTD, INOVIQ stock down 62.6%, including session's moves

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.